Neratinib (Nerlynx®) is accepted for use within NHSScotland

Approved for the extended adjuvant treatment of adult patients with early-stage hormone receptor +ve HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.

Scottish Medicines Consortium